Docetaxel With or Without Oblimersen in Treating Patients With Hormone-Refractory Adenocarcinoma (Cancer) of the Prostate

NCT00085228 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

116

Enrollment

NETWORK

Sponsor class

Conditions

Prostate Cancer

Interventions

BIOLOGICAL: oblimersen sodium
DRUG: docetaxel

Sponsor

European Organisation for Research and Treatment of Cancer - EORTC